Compare MCBS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCBS | COLL |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2019 | 2015 |
| Metric | MCBS | COLL |
|---|---|---|
| Price | $35.00 | $22.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $33.00 | ★ $51.40 |
| AVG Volume (30 Days) | 51.6K | ★ 806.6K |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 4.76 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $36.78 | $8.01 |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $22.78 | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $24.53 | $21.65 |
| 52 Week High | $37.46 | $50.79 |
| Indicator | MCBS | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 28.57 |
| Support Level | $34.58 | N/A |
| Resistance Level | $35.30 | $35.33 |
| Average True Range (ATR) | 0.68 | 0.88 |
| MACD | -0.04 | 0.13 |
| Stochastic Oscillator | 30.68 | 26.24 |
MetroCity Bankshares Inc is a bank holding company. Through its banking subsidiary, it operates as a full-service commercial bank focused on delivering various financial products and services to the small-to medium-sized businesses and individuals in its markets, including many customers in diverse and multi-ethnic communities in metropolitan markets in the Eastern U.S., Texas and California. The company provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers, and a variety of other banking services. The majority of its revenue is generated in the form of interest income.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.